1;Endocannabinoids: synthesis and degradation;5 1.1;Endocannabinoids;5 1.2;Commonalities between anandamide and 2-AG anabolic and catabolic reactions;6 1.3;Anandamide biosynthesis: one or more pathways?;8 1.4;2-AG biosynthesis: perhaps less complicated than originally thought;10 1.5;Biosynthesis of NADA and other endocannabinoids: more questions than answers;12 1.6;The endocannabinoid membrane transporter: an " unknown" between release and re- uptake;12 1.7;Fatty acid amide hydrolase: AEA degradation and beyond;14 1.8;2-AG degradation: redundancy again;15 1.9;Endocannabinoid oxidation and its possible role;17 1.10;Regulation of endocannabinoid levels: what is the target, biosynthesis or degradation?;18 1.11;Conclusions: new therapeutic drugs from studies of endocannabinoid synthesis and degradation;20 1.12;References;21 2;Biological effects of lysophospholipids;29 2.1;Introduction;29 2.2;S1P receptors;32 2.3;LPA receptors;39 2.4;Conclusions and future prospects;44 2.5;References;45 3;Lipoxins: update and impact of endogenous pro- resolution lipid mediators;51 3.1;Introduction;51 3.2;Lipoxin biosynthesis and metabolism;52 3.3;Resolvins;53 3.4;Metabolism;53 3.5;Bioactions of lipoxins;54 3.6;Mechanisms of lipoxin action: receptors and signalling pathways;55 3.7;Transcription factors involved in lipoxin A4 signalling;62 3.8;Lipoxins in inflammation and disease;63 3.9;Intestinal inflammation;64 3.10;Respiratory disease;65 3.11;Glomerulonephritis and renal diseases;65 3.12;Angiogenesis;66 3.13;Tuberculosis;67 3.14;Ocular wound healing;67 3.15;Conclusions;68 3.16;References;68 4;Multi-photon excitation imaging of dynamic processes in living cells and tissues;75 4.1;Introduction;76 4.2;Two-photon absorption and the two-photon microscope;77 4.3;Applications of two-photon microscopy;79 4.4;The future;91 4.5;References;93 5;Lipid homeostasis in macrophages - Implications for atherosclerosis;97 5.1;Macrophages and atherosclerosis;99 5.2;Differential expression of the monocyte innate immunity receptor complex defining monocyte subpopulations;101 5.3;Receptor entry pathways of modified LDL;103 5.4;Specific characteristics of E-LDL and Ox-LDL;105 5.5;Abnormalities of cholesterol trafficking;108 5.6;Cellular cholesterol metabolism and lipid storage;109 5.7;Cholesterol efflux from macrophages to prevent foam cell formation;111 5.8;ABCA1-interacting proteins and lipid membrane microdomains;113 5.9;Regulation of cellular cholesterol levels through transcription factors;115 5.10;Niacin, statins, CETP inhibitors, apoA-I mimetics, and ezetimibe as pharmacological modulators of lipid homeostasis;117 5.11;Conclusion;118 5.12;Glossary;119 5.13;References;120